Flatiron Health IPO
Flatiron Health was a healthcare technology company that specialized in oncology data and analytics, helping cancer researchers and pharmaceutical companies accelerate drug development through real-world evidence. The company built a comprehensive database of cancer patient information and provided software solutions for oncology practices. Investors were interested in Flatiron's potential to transform cancer research and drug development processes.
What We Know
Flatiron Health was acquired by Roche, the Swiss pharmaceutical giant, in February 2018 for approximately $1.9 billion. The acquisition was part of Roche's strategy to enhance its data capabilities and strengthen its position in oncology drug development. Flatiron never went public as an independent company, instead choosing the acquisition route. The acquisition was seen as validation of Flatiron's technology and market position in healthcare data analytics. Roche integrated Flatiron's capabilities into its broader pharmaceutical operations, particularly focusing on leveraging real-world data for drug development and regulatory submissions. Since the acquisition, Flatiron operates as part of Roche's organization rather than as an independent entity.
Frequently Asked Questions
Has Flatiron Health had an IPO?
No, Flatiron Health never had an IPO. The company was acquired by Roche in 2018 for approximately $1.9 billion before it could go public.
When is the Flatiron Health IPO date?
There will be no Flatiron Health IPO date as the company was acquired by Roche in 2018. Flatiron now operates as part of the Swiss pharmaceutical company.
How can I buy Flatiron Health stock?
You cannot buy Flatiron Health stock directly since it was acquired by Roche. To gain exposure to Flatiron's technology, you could consider investing in Roche (ticker: RHHBY) which now owns the company.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts